Screener
Amylyx Pharmaceuticals, Inc. AMLX Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:04 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336682
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Proceeds from financings, net of issuance costs | — | 65,577 |
| Proceeds from exercise of stock options and RSUs vesting | 9,132 | 1,042 |
| Withholding taxes paid on stock-based awards | (4,436) | (988) |
| Net cash provided by financing activities | 4,696 | 65,631 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents | (179) | 805 |
| Net decrease in cash, cash equivalents and restricted cash equivalents | (177,324) | (19,301) |
| Cash, cash equivalents and restricted cash equivalents, beginning of period | 227,636 | 78,837 |
| Cash, cash equivalents and restricted cash equivalents, end of period | $50,312 | $59,536 |
Item 1. Financial Statements.
FAQ
- What is Amylyx Pharmaceuticals, Inc.'s financing cash flow?
- Amylyx Pharmaceuticals, Inc. (AMLX) reported financing cash flow of $1.48M in Q2 2026.
- What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s financing cash flow?
- Over 2 years (2021 to 2024), Amylyx Pharmaceuticals, Inc.'s financing cash flow has grown at a -95.3% compound annual growth rate (CAGR), from $159.57M to $348K.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Amylyx Pharmaceuticals, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude